Sofinnova Investments, Inc. Nu Cana PLC Transaction History

Sofinnova Investments, Inc.

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Aug 14, 2024	BUY	$0.26 - $0.42 $884,192 - $1.43 Million	3,400,739 New	3,400,739 $884,000
Q1 2024 May 15, 2024	SELL	$0.26 - $0.42 $333,679 - $539,020	-1,283,381 Reduced 27.4%	3,400,739 $884,000
Q4 2023 Aug 15, 2024	BUY	$0.26 - $0.8 $1.22 Million - $3.75 Million	4,684,120 New	4,684,120 $1.41 Million
Q4 2023 Feb 12, 2024	SELL	$0.26 - $0.8 $238,128 - $732,703	-915,879 Reduced 16.35%	4,684,120 $1.41 Million
Q3 2020 Nov 13, 2020	BUY	$4.57 - $6.48 $15.2 Million - $21.6 Million	3,333,333 Added 147.06%	5,599,999 $29 Million
Q4 2018 Feb 14, 2019	BUY	$13.0 - $22.57 $20.8 Million - $36.1 Million	1,600,000 Added 240.0%	2,266,666 $32.9 Million
Q2 2018 Aug 14, 2018	SELL	$19.0 - $29.84 $76 Million - $119 Million	-4,000,000 Reduced 85.71%	666,666 $12.7 Million
Q1 2018 May 15, 2018	BUY	$10.04 - $28.25 $46.9 Million - $132 Million	4,666,666 New	4,666,666 $88.3 Million

3.33M

Ticker NCNA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,196,000
Market Cap $69.9M
Description
NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer. The company develops its products based on its proprietary ProTide technology. Its lead product candidate includes Acelarin, which is in Phase I clinical trial for patients with advanced solid tumors; Phase Ib for patients ...

Get notified when there are updates to the investment portfolio of Sofinnova Investments, Inc., based on Form 13F filings with the SEC.

Stay updated on Sofinnova Investments, Inc. with notifications on news.